SynthesisPediatric research2026
Current guidelines on screening, diagnosis and management of dyslipidaemia in childhood: a systematic review.
Synthesis in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly identification and treatment of lipid disorders has the potential to improve long-term cardiovascular health in affected individuals. We performed a systematic review of guidelines on screening, diagnosis, and management of dyslipidaemias in children.
methodsWe searched Medline, Embase, and selected websites for relevant clinical practice recommendations/guidelines, published in English/German from 01.01.2018 to 31.01.2025. We used AGREE II tool to assess guidelines' quality.
resultsSix national guidelines, mainly on familial hypercholesterolemia (FH), were included. Recommendations for universal screening for dyslipidaemias in childhood differed, ranging from the statement of insufficient evidence (n = 1) or negative recommendation of the national screening committee (n = 1) through weak (n = 2) to moderate (n = 1) recommendations to consider population screening. All organizations recommended statins as a first-line drug therapy in children with FH (strong recommendation). Behavioral intervention was mainly strongly recommended as an additional treatment component of FH, and as therapy of choice in childhood obesity related dyslipidaemia. Guidelines applied different systems to categorize certainty of evidence and strength of recommendations. 50% of guidelines scored high (>70%) for rigor of development.
conclusionsCurrent guidelines provide overall consistent recommendations for the management of childhood dyslipidaemias, but show lack of consensus regarding universal screening for early detection of lipid disorders. IMPACT: Health behavior counseling is recommended for all children affected with dyslipidaemia. Statins are consistently proposed as a first-line drug therapy in pediatric familial hypercholesterolemia. Recommendations for universal screening for dyslipidaemias in childhood vary. This systematic review provides insights into current recommendations on pediatric lipid disorders, explores potential reasons for discrepancies, and indicates the need for consensus on the optimal strategy for early identification of familial hypercholesterolemia.
Indexed as
Identifiers
41238902What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.